Aprea Therapeutics Inc (APRE)

Aprea Therapeutics (NASDAQ:APRE) Receives “Buy” Rating from HC Wainwright - Defense World

Defense World

Aprea Therapeutics Hosts Virtual Event on Promising Cancer Therapy - MyChesCo

MyChesCo

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

MSN

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 - ForexTV.com

ForexTV.com

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

GlobeNewswire Inc.

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

MSN

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

MSN

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

MSN

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

MSN

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

MSN

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

MSN

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MyChesCo

MyChesCo

Aprea Therapeutics (NASDAQ:APRE) Given Buy Rating at HC Wainwright - Defense World

Defense World

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor - EIN News

EIN News

Amplitude, Inc. (NASDAQ:AMPL) Short Interest Up 34.5% in May - Defense World

Defense World

Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Up 36.0% in May - Defense World

Defense World

Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Decreases By 34.6% - Defense World

Defense World

Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Rises By 47.0% - Defense World

Defense World

Aprea Therapeutics Insiders Lose Out As Stock Sinks To US$4.23 - Simply Wall St

Simply Wall St

Aprea Therapeutics Insiders Lose Out As Stock Sinks To US$4.23 - Simply Wall St

Simply Wall St

Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock - Yahoo Finance

Yahoo Finance

Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock - Yahoo Finance

Yahoo Finance

Aprea Therapeutics Advances Cancer Treatment Trial to Higher Dose Level - MyChesCo

MyChesCo

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 64.3% in May - Defense World

Defense World

Aprea advances cancer drug ATRN-119 in clinical trial By Investing.com - Investing.com

Investing.com

Acute Myeloid Leukemia Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies ... - openPR

openPR

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

GlobeNewswire Inc.

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at ... - Yahoo Finance

Yahoo Finance

Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year? - Yahoo New Zealand News

Yahoo New Zealand News

Ovarian Cancer Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per - EIN News

EIN News

Aprea Therapeutics, Inc. (NASDAQ:APRE) to Post Q2 2024 Earnings of ($0.69) Per Share, Wedbush Forecasts - Defense World

Defense World

Aprea Therapeutics, Inc. (NASDAQ:APRE) to Post Q2 2024 Earnings of ($0.69) Per Share, Wedbush Forecasts - Defense World

Defense World

Wedbush Analysts Lower Earnings Estimates for Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World

Defense World

Aprea Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.58) Per Share, HC Wainwright Forecasts (NASDAQ:APRE) - Defense World

Defense World

Wedbush Analysts Lower Earnings Estimates for Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World

Defense World

ArriVent BioPharma Bolsters Board with Biopharmaceutical Expert Dr. John Hohneker - MyChesCo

MyChesCo

Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials - MSN

MSN

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update - Defense World

Defense World

Learn to Evaluate (APRE) using the Charts - Stock Traders Daily

Stock Traders Daily

Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials - MyChesCo

MyChesCo

Aprea Therapeutics' (APRE) Outperform Rating Reaffirmed at Wedbush - Defense World

Defense World

Aprea Therapeutics' (APRE) Buy Rating Reaffirmed at HC Wainwright - Defense World

Defense World

Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials - MyChesCo

MyChesCo

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update - Investing.com India

Investing.com India

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

GlobeNewswire Inc.

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference - Yahoo Finance

Yahoo Finance

Mineralys Therapeutics Reports Robust Financial Results for Q1 2024 - MyChesCo

MyChesCo

Mineralys Therapeutics Reports Robust Financial Results for Q1 2024 - MyChesCo

MyChesCo

Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions? - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion - MyChesCo

MyChesCo